Abstract: Androgen insensitivity (testicular feminization)
Introduction
Androgen insensitivity (testicular feminization) syndrome is a rare inherited form of male pseudohermaphroditism that occurs in a phenotypically normal woman with male karyotype (XY). 1 The first medical report on Androgen insensitivity syndrome (AIS) was published in 1953 by J.M. Morris, an American gynaecologist. The syndrome was designated -testicular feminization syndrome‖ because testes produces hormones with oestrogen like actions. 2 AIS results from an androgen receptor defect. The probable explanation of the syndrome is the absence of the cytosol androgen binding protein receptor that is normally present in the androgen responsive tissues. So the male fetus is not stimulated by normal levels of circulating androgens. As a result, there is no fusion of the genital folds to form the scrotum and penis and no posterior migration of the labioscrotal folds. 1 The estimated prevalence of AIS is between 1 in 20,000 and 1 in 99,000 genetic males. AIS is thought to be related to approximately 6-10% of cases of primary amenorrhea. 3 The aim of this paper is to present the importance and diagnosis of a case of CAIS and discussions that follow it.
II. Case Report
A 20 year old woman was admitted for investigations of primary amenorrhea. Physical examination revealed a female phenotype with normal development of breasts and normal external genitalia but with absence of hair in the groins and axillary area (Figure 1 ). Systemic examination revealed a firm mass measuring 5x3 cms in the left inguinal region. Gynecological examination revealed a short blind vagina (3 cms in length) with absence of uterus and cervix.
Magnetic resonance imaging showed a well defined lesion measuring 5.4 x 2.3 cms in left inguinal region suggestive of testicular parenchyma and ovarian follicles. A cystic lesion measuring 6.8 x 5.5 cms with a well-defined solid altered signal area adjacent to it measuring 3.3x3 cms was seen in the pelvis on right side. Hormonal assay showed FSH levels of 13.9mIU/ml, elevated LH levels of 29.8mIU/ml and serum testosterone levels of 551.99ng/dL. Tumour markers revealed serum βHCG -<1.2mIU/mL, serum AFP -0.44IU/mL and LDH -436 IU/L. A karyotype was also performed which revealed a 46 XY complement.
In view of these findings, a diagnosis of Complete androgen insensitivity syndrome was made. The patient was counselled regarding the need for gonadectomy in view of increased risk of malignancy and also regarding the need for lifelong hormone replacement therapy. Bilateral gonadectomy was done by laparoscopy and the specimen sent for histopathological examination (Figure 2 ).
Gross examination of the left gonadectomy specimen revealed a smooth, glistening mass with a solid grey-brown cut surface (Figure 3 ). Microscopy showed seminiferous tubules lined predominantly by Sertoli cells with peritubular fibrosis (Figure 4 ). Germ cells were reduced in number with maturation arrest at primary and secondary spermatocyte stage. The lumen did not show mature spermatozoa. The interstitium showed Leydig cell hyperplasia.
Gross examination of the right gonadectomy specimen revealed a smooth, glistening mass with a solid grey-brown cut surface along with a unilocular cyst measuring 5x2 cms (Figure 3 ). Microscopy showed solid and cystic components. The solid component consisted of immature testicular tissue with maturation arrest of spermatogonia. The interstitium showed Leydig cell hyperplasia. The cystic component showed a Wolffian cyst lined by cuboidal, predominantly non ciliated, epithelium resting on the well-developed basement membrane ( Figure 5 ). No signs of testicular cancer were identified in both the gonads.
The patient was put on oestrogen therapy and informed that she could have a normal sexual life but would be infertile.
III. Discussion
Testicular Feminization, or Androgen Insensitivity Syndrome, is a rare disease when a male, genetically XY, because of various abnormalities of the X chromosome, has some physical characteristics of a woman, or even a full female phenotype. 4 Based on genital phenotype AIS is traditionally classified into 3 clinical subgroups -Complete, Partial and Mild. Complete Androgen Insensitivity Syndrome (CAIS) individuals have normal female external genitalia and typically present either before puberty with masses in the inguinal canal that are subsequently identified as testes or at puberty with primary amenorrhea and sparse to absent pubic and/or axillary hair. Partial Androgen Insensitivity Syndrome (PAIS) individuals are predominantly female, predominantly male, or ambiguous genitalia with signs of external genital masculinization including clitoromegaly or posterior labial fusion. Mild Androgen Insensitivity Syndrome (MAIS) individuals have typical male genitalia and usually present with gynaecomastia at puberty while in some instances, the only observed abnormality appears to be male infertility. 5 CAIS, also known as Morris syndrome, results from an absence or abnormal cytosol receptor for androgens. Thus, despite possessing a male karyotype (46XY), phenotypically patient presents as an asymptomatic female usually discovered during the perimenarchal stage when the individual fails to menstruate. The testis is often undescended and the ovaries, uterus, fallopian tubes, and upper third of vagina are typically absent. Externally, the labia majora and minora are usually well formed. 6 The underlying cause is a mutation in the androgen receptor gene localized in the long arm of X chromosome Xq11-12.2. Although 70% of these mutations are X-linked recessive, 30% can also be sporadic de novo mutations. 7 During the 6 th week of male foetal development, under the influence of the SRY gene located on the Y chromosome, the testes begin to differentiate from the genital ridges. Leydig cells appear through the end of the 8 th week, and they start producing testosterone. In the absence of testosterone, female sexual characteristics develop. 8 Gonadectomy is currently recommended for AIS with cryptorchidism due to high risk of germ cell malignancy. The risk of malignancy of undescended intra-abdominal testes is 3.6% at 25 years and 33% at 50 years. 9 Hormone replacement therapy is required after gonadectomy, and should be modulated over time to replicate the hormone level naturally present in the body during various stages after puberty. 10 Thus, CAIS is a rare disease that must be diagnosed and treated through close work between gynaecologists, endocrinologists, pathologists and psychiatrists. 4 
IV. Figures
Fig1: Physical examination revealed normal development of breasts and normal external genitalia but with absence of hair in the groins and axillary area. 
